

11 October 2023

Change of company name and ASX code

Perth, Australia, and Minneapolis, USA: Medibio Limited ('the Company') (ASX: MEB) (OTCPINK: MDBIF) is pleased to confirm that a resolution was passed by shareholders on Friday, 6 October 2023 at the Company's General Meeting to change its name from Medibio Limited to TrivarX Limited.

TrivarX will commence trading under its new name and ASX code of "TRI" from the beginning of trade on Monday, 16 October 2023.

The new Company name represents TrivarX's ongoing commitment to realise a new level of integrated care at the nexus of physical health, mental health and sleep health by delivering a clinically-backed sleep diagnostics solution that provides an objective assessment of how sleep health is correlated with other health variables.

The Company is confident that the introduction of its innovative physical, mental and sleep health care model will provide solid framework for the objective diagnosis of mental health conditions via healthcare providers and systems globally.

In that context, TrivarX has already established strong momentum through its recent clinical trial initiatives, including strong results from its Phase 1 Sleep Signal Analysis for Current Major Depressive Episode study (SAMDE) trial (refer ASX announcement: 24 July 2023).

The Company is in the process of updating its digital assets, including TrivarX's website (www.trivarx.com) and operating divisions across the USA. This is expected to complete in the coming weeks.

Management commentary:

Non-Executive Chairman, Mr David Trimboli said: *"The change of company name and ASX code follows an extensive review of the Company's operations, as well as a number of new Director appointments which left the Company well placed to advance its suite of clinically-backed medical solutions along a clearly-defined commercialisation pathway.*

"As TrivarX continues to progress its Phase 2 SAMDE trial and fast track the roll-out of its sleep research solutions to R&D providers and centres across the US, we believe the new Company name and branding will allow us to cement our position as an emerging, innovative technology provider in one of the world's largest markets.

"On behalf of the Board and management, I look forward to providing ongoing operational updates as developments materialise."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

ASX ANNOUNCEMENT



Investor Enquiries:

investors@medibio.com.au

+61 8 6189 1155

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au